Cover Image
市場調查報告書

癌症疫苗相關各種合作契約:交易趨勢,企業,財務及預測

Global Cancer Vaccine Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 233051
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症疫苗相關各種合作契約:交易趨勢,企業,財務及預測 Global Cancer Vaccine Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts
出版日期: 2016年10月06日 內容資訊: 英文 190 Pages
簡介

本報告提供企業的癌症疫苗的合作夥伴交易的方法與理由分析,彙整生物醫藥品市場上癌症疫苗交易趨勢,主要交易,及補助藥·藥物輸送交易·合作分析,癌症疫苗交易結構分析,癌症疫苗交易一覽等資訊。

摘要整理

第1章 簡介

第2章 癌症疫苗的交易趨勢

  • 簡介
  • 過去數年的癌症疫苗交易
  • 癌症疫苗合作最活躍的企業/機關
  • 癌症疫苗合作:各交易類型
  • 癌症疫苗合作:各治療領域
  • 癌症疫苗合作所明確開出的金融條件
    • 交易總額
    • 預付款付款額
    • 目標達成褒獎金
    • 權利金比率

第3章 主要交易

  • 簡介
  • 主要的癌症疫苗交易:各交易金額

第4章 對癌症疫苗最積極的交易企業

  • 簡介
  • 對癌症疫苗最積極的交易企業
  • 對癌症疫苗最積極的合作企業簡介

第5章 癌症疫苗契約交易一覽

  • 簡介
  • 癌症疫苗契約交易一覽

第6章 癌症疫苗契約:各技術類型

第7章 合作資源中心

  • 線上合作
  • 合作趨勢
  • 相關資料

附錄

  • 附錄1:藥物輸送契約(各企業A-Z)
  • 附錄2:藥物輸送契約(各開發階段)
    • 藥物研發
    • 前臨床
    • 階段Ⅰ
    • 階段Ⅱ
    • 階段Ⅲ
    • 法規
    • 上市
    • 處方
  • 附錄3:藥物輸送契約(各類型)
    • 資產購買
    • 轉讓
    • 大型製藥公司的對外授權
    • 共同開發
    • 共同R&D
    • 共同上市
    • 共同促銷
    • CRADA
    • 交叉授權
    • 開發
    • 流通銷售
    • 股票購買
    • 評估
    • 轉讓
    • 合資企業
    • 授權
    • 訴訟
    • 製造
    • 行銷
    • 物質移動
    • 選擇
    • 推銷
    • 研究
    • 協定
    • 衍生公司
    • 輔助許可證
    • 供給
    • 技術轉移
    • 契約解除
    • 保證
  • 附錄4:癌症疫苗契約(各治療領域)
  • 附錄5:契約類型定義

關於Wildwood Ventures

Current Partnering Current Agreements CurrentPartnering的發行標題

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP22011

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 210 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Vaccine dealmaking with a brief summary followed by a comprehensive listing of Cancer Vaccine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.

Key benefits

Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Cancer Vaccine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
  • Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
  • Identify most active Cancer Vaccine dealmakers since 2010
  • Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Terms and Agreements includes:

  • Trends in Cancer Vaccine dealmaking in the biopharma industry since 2010
  • Analysis of Cancer Vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Cancer Vaccine deals
  • Access to Cancer Vaccine contract documents
  • Leading Cancer Vaccine deals by value since 2010
  • Most active Cancer Vaccine dealmakers since 2010

In Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts , the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 210 Cancer Vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Cancer Vaccine Partnering 2010-2016 report provides the reader with the following key benefits:

  • In-depth understanding of Cancer Vaccine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
  • Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
  • Identify most active Cancer Vaccine dealmakers since 2010
  • Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking

  • 2.1. Introduction
  • 2.2. Cancer Vaccine partnering over the years
  • 2.3. Most active Cancer Vaccine dealmakers
  • 2.4. Cancer Vaccine partnering by deal type
  • 2.5. Cancer Vaccine partnering by therapy area
  • 2.6. Deal terms for Cancer Vaccine partnering
  • 2.6.1 Cancer Vaccine partnering headline values
  • 2.6.2 Cancer Vaccine deal upfront payments7
  • 2.6.3 Cancer Vaccine deal milestone payments
  • 2.6.4 Cancer Vaccine royalty rates

Chapter 3 - Leading Cancer Vaccine deals

  • 3.1. Introduction
  • 3.2. Top Cancer Vaccine deals by value

Chapter 4 - Most active Cancer Vaccine dealmakers

  • 4.1. Introduction
  • 4.2. Most active Cancer Vaccine dealmakers
  • 4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 - Cancer Vaccine contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Cancer Vaccine deals by company A-Z

Appendix 2 - Cancer Vaccine deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Cancer Vaccine deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Cancer Vaccine deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Cancer Vaccine partnering since 2010
  • Figure 2: Active Cancer Vaccine dealmaking activity- 2010 to 2016
  • Figure 3: Cancer Vaccine partnering by deal type since 2010
  • Figure 4: Cancer Vaccine partnering by disease type since 2010
  • Figure 5: Cancer Vaccine deals with a headline value
  • Figure 6: Cancer Vaccine deals with an upfront value
  • Figure 7: Cancer Vaccine deals with a milestone value
  • Figure 8: Cancer Vaccine deals with a royalty rate value
  • Figure 9: Top Cancer Vaccine deals by value since 2010
  • Figure 10: Most active Cancer Vaccine dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top